Risk factors for cognitive problems in breast cancer patients: the role of brain white matter
- Conditions
- cognitive declinememory and concentration problems10009841
- Registration Number
- NL-OMON38553
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 114
-participation in study PROSPECT, NL32148.031.10;Inclusion criteria PROSPECT study (all groups):
-female
-age < 70 (to allow for the use of the same neuropsychological test battery in all participants)
-sufficient proficiency in the Dutch language;Experimental group:
-newly diagnosed breast cancer patients without distant metastases who will receive anthracycline-based adjuvant chemotherapy;Breast cancer control group:
-newly diagnosed breast cancer patients without distant metastases who do not require chemotherapy;Healthy control group:
-healthy females, matched for age
All groups:
-new malignancies, except for basal cell carcinoma
-excessive use of alcohol of drugs
-use of psychotropic medication
-neurologic or psychiatric disorders that may influence cognitive functioning
-conditions that preclude MRI examination (e.g., pacemaker);Experimental group and breast cancer control group:
-relapse and/or metastases
-treatment with trastuzumab (Herceptin)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method